1 publication

  • Published Subscription Review Article

    Pharmacological Review On Enzalutamide

    Abstract: A key therapeutic option in the treatment of prostate cancer, especially metastatic castration-resistant prostate cancer (mCRPC), is Enzalutamide, a second-generation anti androgen drug. Enzalutamide, discovered by Charles Sawyer and Michael Jung at the University of California, Los Angeles, was developed and Food and Drug Administration (FDA)-approved in 2012. Its therapeutic significance was further solidified with subsequent extensions in indications to encompass metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer. …

    Published in Trends in Drug Delivery · Vol. 11, Issue 2, 2024 · pp. 7–15 Read article

Read more of it

Subscribe to one journal or build your own list of several. One invoice, one payment, access for a full year.

Subscribe to journals →

Publish your article

Peer-reviewed journals across every subject, with open access options. Send your manuscript to the right editor today.

Publish with us → Calculate your APC
Support